Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares...
March 27 2017 - 4:04PM
Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, today announced the
closing of its previously announced public offering of 7,854,500
shares of common stock, including 1,024,500 shares sold pursuant to
the underwriters’ exercise in full of their option to purchase
additional shares. Gross proceeds from the offering at a public
offering price of $10.25 per share, before underwriting discounts
and commissions and offering expenses, were approximately $80.5
million.
Leerink Partners acted as sole book-running manager
for the offering. Wells Fargo Securities acted as lead manager and
JMP Securities acted as co-manager for the offering.
A shelf registration statement relating to the
offered shares of common stock was filed with the Securities and
Exchange Commission (SEC), and was declared effective on November
24, 2015. A final prospectus supplement and accompanying
prospectus relating to the offering have been filed with the SEC
and are available on the SEC’s website, located at
www.sec.gov. Copies of the prospectus related to the offering
may be obtained from Leerink Partners LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA,
02110, by email at syndicate@leerink.com, or by telephone at (800)
808-7525, ext. 6132.
This press release shall not constitute an offer to
sell or a solicitation of an offer to buy these securities nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer. Calithera is
headquartered in South San Francisco, California.
Investor Relations Contact:
Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Sep 2023 to Sep 2024